MedTrace Logo

Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02176200 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2014-07-14

No results posted yet for this study

Summary

Study to compare the lung and oropharyngeal deposition of Berodual® (fenoterol hydrobromide 50μg + ipratropium bromide 20μg /1x puff) delivered via the Respimat® inhaler and the same dose of Berodual® delivered via an hydrofluoroalkane (HFA) - metered dose inhaler (2 x puffs ) in COPD patients at different inspiratory flow rates.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Berodual® Respimat®, low inspiratory flow rate

DRUG

Berodual® Respimat®, medium inspiratory flow rate

DRUG

Berodual® Respimat®, high inspiratory flow rate

DRUG

Berodual® HFA-MDI, low inspiratory flow rate

DRUG

Berodual® HFA-MDI, medium inspiratory flow rate

DRUG

Berodual® HFA-MDI, high inspiratory flow rate

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2004-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02176200 on ClinicalTrials.gov